12Maruho has declared to reinforce its ability to create new products for the enhancement of its pipeline as the top-priority task in its research and development. In the Fourth Medium-Term Plan, we set “Create products for the global market” as a key strategy, demonstrating a significant shift from in-house drug discovery to drug discovery based on global collaborations in view of the escalating trend of globalization in new drug development. For R&D activities in Japan, we will narrow down our target therapeutic areas so that resources can be concentrated. Both inside and outside Japan, we will deepen partnerships with companies and academia with the aim of developing globally competitive new drugs.Initiatives to generate innovations Maruho Shonan Innovation Lab (MSiL), opened in the Shonan Health Innovation Park as a next-generation research center in 2019, is engaged in creating new products through collaborations based on industry-academia-government networks both inside and outside Japan. We are focused on Israel, a country referred to as the “Silicon Valley of the Middle East” boasting high abilities and speed in research and development. We established Maruho Israel Innovation Fund GmbH & Co. KG in 2018 to invest in promising research institutes and ventures overseas, and Maruho Israel Innovation Labs Ltd. to support the investees. To date, by utilizing local connections, we have established a collaboration system to expand our development pipeline, and are currently evaluating and selecting projects from major academic institutions and ventures overseas as in-licensing candidates. Maruho is also focusing on initiatives to satisfy unmet medical needs, such as concluding new in-licensing agreements to enhance its pipeline in the area of cancer supportive care.In research and development, Maruho places emphasis on creating new products, which is to say, the ability to create new things. Maruho is also committed to research and development of medical drugs focusing on topical treatments in dermatology. Maruho’s strength is its capabilities in late-stage development including addition of various dosage forms and indications based on its unique topical drug formulation technology, also known as “nurturing capabilities.” (▶︎ P.13 “Development Pipeline”) Moreover, taking advantage of its position as an unlisted company, Maruho allocates investments from a medium- to long-term perspective. For research and development, we make active investments even in high-risk, high-return projects and rare diseases if they lead to social contributions.Create products for the global marketResearch and DevelopmentR&D capabilities rooted in knowledge and know-how regarding topical drugs in dermatology
元のページ ../index.html#14